These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16798723)

  • 1. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.
    Anan A; Baskin-Bey ES; Isomoto H; Mott JL; Bronk SF; Albrecht JH; Gores GJ
    Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G709-16. PubMed ID: 16798723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse.
    Canbay A; Feldstein A; Baskin-Bey E; Bronk SF; Gores GJ
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1191-6. PubMed ID: 14617689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
    Maseda D; Meister S; Neubert K; Herrmann M; Voll RE
    Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
    Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.
    Yanaba K; Yoshizaki A; Muroi E; Hara T; Ogawa F; Shimizu K; Sato S
    J Leukoc Biol; 2010 Jul; 88(1):117-22. PubMed ID: 20418448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
    Mortenson MM; Schlieman MG; Virudachalam S; Lara PN; Gandara DG; Davies AM; Bold RJ
    Lung Cancer; 2005 Aug; 49(2):163-70. PubMed ID: 16022909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
    Fahy BN; Schlieman MG; Mortenson MM; Virudachalam S; Bold RJ
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):46-54. PubMed ID: 15791457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biliary intervention aggravates cholestatic liver injury, and induces hepatic inflammation, proliferation and fibrogenesis in BDL mice.
    Wen YA; Liu D; Zhou QY; Huang SF; Luo P; Xiang Y; Sun S; Luo D; Dong YF; Zhang LP
    Exp Toxicol Pathol; 2011 Mar; 63(3):277-84. PubMed ID: 20149605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
    Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibition: mechanism of action.
    DeMartino GN
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S5-9. PubMed ID: 19791423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibition induces hepatic stellate cell apoptosis.
    Anan A; Baskin-Bey ES; Bronk SF; Werneburg NW; Shah VH; Gores GJ
    Hepatology; 2006 Feb; 43(2):335-44. PubMed ID: 16440346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
    Chu S; Alexiadis M; Fuller PJ
    Reprod Sci; 2009 Apr; 16(4):397-407. PubMed ID: 19087975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice.
    Van Herck JL; De Meyer GR; Martinet W; Bult H; Vrints CJ; Herman AG
    Basic Res Cardiol; 2010 Jan; 105(1):39-50. PubMed ID: 19693627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
    Subklewe M; Sebelin-Wulf K; Beier C; Lietz A; Mathas S; Dörken B; Pezzutto A
    Hum Immunol; 2007 Mar; 68(3):147-55. PubMed ID: 17349869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
    Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
    Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition promotes functional recovery after peripheral nerve reperfusion injury.
    Park JW; Kim KM; Oh KJ; Rhyu IJ; Jang HS
    J Trauma; 2009 Mar; 66(3):743-8. PubMed ID: 19276748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.
    Schmidt N; Gonzalez E; Visekruna A; Kühl AA; Loddenkemper C; Mollenkopf H; Kaufmann SH; Steinhoff U; Joeris T
    Gut; 2010 Jul; 59(7):896-906. PubMed ID: 20581238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
    Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.